Analyst picks & changes

Vertex Pharmaceuticals Inc.

(VRTX)

Cowen & Co. analyst David Stone said the Cambridge, Mass., company's HIV protease inhibitor,

VX-478

, is potentially superior to Merck's drug.

In 28-day primate studies, VX-478 was

Read the full 334 word article

How to gain access

Continue reading with a
two-week free trial.